Literature DB >> 8159005

Multidisciplinary treatment of biliary tract cancers.

W G Kraybill1, H Lee, J Picus, G Ramachandran, M J Lopez, N Kucik, R J Myerson.   

Abstract

Ninety-six patients referred for radiation therapy to Washington University affiliated institutions with tumors of the extrahepatic biliary tree form the basis of this report. Patients were examined with regard to demographic factors, tumor primary site, presenting symptoms, methods of diagnosis, and methods of management. The median survival of all 96 patients in this series was 11 months. There was no significant difference between patients with gallbladder cancer and patients with cancer of the biliary ductal system. There was a statistically significant improvement in survival in those patients undergoing resection as management or as a component of the management of their tumors (P = 0.02). Patients receiving > 4,000 cGy of radiation therapy had an improved survival compared to those patients receiving < or = 4,000 cGy of radiation therapy (P = 0.003). While surgical resection improved survival for those patients undergoing removal of all gross tumor, this effect was noted especially in patients with gallbladder cancer.

Entities:  

Mesh:

Year:  1994        PMID: 8159005     DOI: 10.1002/jso.2930550408

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  9 in total

Review 1.  Current state of nonsurgical therapies for cholangiocarcinoma.

Authors:  Volker Brass; Jan B Kuhlmann; Hubert E Blum
Journal:  Hepat Oncol       Date:  2013-12-20

Review 2.  Chemotherapy and targeted therapy for gall bladder cancer.

Authors:  Bhawna Sirohi; Ashish Singh; P Jagannath; Shailesh V Shrikhande
Journal:  Indian J Surg Oncol       Date:  2014-06-03

3.  Salvage radiotherapy for locoregionally recurrent extrahepatic bile duct cancer after radical surgery.

Authors:  Eunji Kim; Yi-Jun Kim; Kyubo Kim; Changhoon Song; Jae-Sung Kim; Do-Youn Oh; Eun Mi Nam; Eui Kyu Chie
Journal:  Br J Radiol       Date:  2017-10-09       Impact factor: 3.039

Review 4.  Current management of gallbladder carcinoma.

Authors:  Andrew X Zhu; Theodore S Hong; Aram F Hezel; David A Kooby
Journal:  Oncologist       Date:  2010-02-10

5.  A phase II study of adjuvant gemcitabine plus docetaxel followed by concurrent chemoradation in resected pancreaticobiliary carcinoma.

Authors:  May Cho; Andrea Wang-Gillam; Robert Myerson; Feng Gao; Steven Strasberg; Joel Picus; Steven Sorscher; Chloe Fournier; Gayathri Nagaraj; Parag Parikh; Rama Suresh; David Linehan; Benjamin R Tan
Journal:  HPB (Oxford)       Date:  2015-03-20       Impact factor: 3.647

6.  Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study.

Authors:  Kerry J Williams; Joel Picus; Kim Trinkhaus; Chloe C Fournier; Rama Suresh; Joan S James; Benjamin R Tan
Journal:  HPB (Oxford)       Date:  2010-08       Impact factor: 3.647

7.  Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors.

Authors:  A Nakeeb; H A Pitt; T A Sohn; J Coleman; R A Abrams; S Piantadosi; R H Hruban; K D Lillemoe; C J Yeo; J L Cameron
Journal:  Ann Surg       Date:  1996-10       Impact factor: 12.969

8.  Impact of adjuvant external beam radiotherapy on survival in surgically resected gallbladder adenocarcinoma: a propensity score-matched Surveillance, Epidemiology, and End Results analysis.

Authors:  Omar Hyder; Rebecca M Dodson; Teviah Sachs; Matthew Weiss; Skye C Mayo; Michael A Choti; Christopher L Wolfgang; Joseph M Herman; Timothy M Pawlik
Journal:  Surgery       Date:  2013-07-19       Impact factor: 3.982

9.  Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: which is better in patients with radically resected extrahepatic biliary tract cancer?: a non-randomized, single center study.

Authors:  Kyu-Hyoung Lim; Do-Youn Oh; Eui Kyu Chie; Jin-Young Jang; Seock-Ah Im; Tae-You Kim; Sun-Whe Kim; Sung Whan Ha; Yung-Jue Bang
Journal:  BMC Cancer       Date:  2009-09-27       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.